AstraZeneca Patent-Cliff Exposure & CMS Drug Spending Portfolio

AstraZeneca (Wilmington, DE): 46 reconciled FDA prescription therapies (40.6% 2025 to 2030 cliff risk), $17.59B 2024 CMS Part D & Medicaid spend, and 26 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterWilmington, DE
Reconciled FDA Portfolio Therapies46
2025 to 2030 Patent-Cliff Revenue Exposure40.6%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$17.59B
2024 Medicare Part D Spend$14.31B
2024 Medicaid Spend$3.29B
California HCAI SB 17 Filings26 WAC filings (max 24.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.